We also confirmed that our in-house generated anti-HER2 IgG1-WT was in sequence and functionally identical to commercial trastuzumab, comparing binding to HER2+ cells, binding to FcγRIIIa on NK cells, and the ability to engender NK cell–mediated ADCC of cancer cells (Supplementary Fig. S4). Here, ERBB2 is linked to cancer.